Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ILAG vs MAIA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ILAG Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–4 Matrix Metrics)

ILAG Overall Winner 6-Pillar Tally: ILAG 3 – 1 MAIA (2 Tie) Matrix Metrics: ILAG 5 – 4 MAIA

As of Nov 20, 2026, Intelligent Living Application Group Inc. (ILAG) is the stronger overall head-to-head candidate over MAIA Biotechnology, Inc. (MAIA) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ILAG carries a Unified Composite Score of 49.6/100 (HOLD) at $1.53 (N/M Forward P/E, -279.6% operating margin), whereas MAIA carries 37.6/100 (SELL) at $1.11 (1.2x Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: ILAG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2); meanwhile MAIA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ILAG vs MAIA
ILAG NASDAQ Head-to-Head Winner
Intelligent Living Application Group Inc. Ordinary Shares
Partitions, Shelvg, Lockers, & Of Fice & Store Fixtures
$1.53
-16.85% 1D
Market Cap $3.3M
TTM Revenue $4.5M
Forward P/E N/M
Beta / 30D Vol 0.81β · 94% Vol
Unified Composite Score
49.6 / 100 HOLD
Tech 38.0 Fund 69.0 Flow 50.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.8%), weak momentum, RSI 32
RSI-14: 32.2 · SMA20: $1.93 · SMA50: $2.50
MAIA NYSE American
MAIA Biotechnology, Inc.
Pharmaceutical Preparations
$1.11
-2.63% 1D
Market Cap $68.5M
TTM Revenue N/A
Forward P/E 1.2x
Beta / 30D Vol 1.65β · 108% Vol
Unified Composite Score
37.6 / 100 SELL
Tech 40.0 Fund 38.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 48.8 · SMA20: $1.11 · SMA50: $1.17

6-Pillar Scorecard Institutional Category Breakdown (ILAG 3 – 1 MAIA)

Columns: Metric · ILAG · MAIA
1. Valuation Multiples MAIA
Forward P/E N/M 1.2x
Trailing P/E N/M 1.2x
PEG Ratio N/M N/M
EV / Revenue 0.7x N/M
2. Growth & Scale ILAG
Revenue Growth (YoY) +2.3% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $4.5M N/A
Market Cap $3.3M $68.5M
3. Profitability & Quality ILAG
Gross Margin 1.2% N/A
Operating Margin -279.6% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -215.3% -341.5%
4. Balance Sheet & Cash Flow ILAG
Cash Generation (TTM) -$12M EBITDA -$20M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.66 Book/Sh · -215.3% ROE $0.24 Book/Sh · -341.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Building Products & Equipment Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ILAG (5) vs MAIA (4)
Institutional Metric ILAG MAIA Criterion Row Edge
Market Capitalization
Scale
$3.3M $68.5M Larger Scale MAIA
Trailing P/E Ratio
Valuation
N/M 1.2x Lower Multiple MAIA
Forward P/E Ratio
Valuation
N/M 1.2x Lower Multiple MAIA
Revenue Growth (YoY)
Growth
+2.3% +0.0% Higher Growth ILAG
Operating Margin (TTM)
Profitability
-279.6% 0.0% Higher Margin MAIA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-215.3% -341.5% Higher ROE ILAG
52-Week Range Position
Momentum
18% ($0–$7) 10% ($1–$3) Stronger Trend ILAG
Beta / 30D Volatility
Risk Regime
0.81β · 94% Vol 1.65β · 108% Vol Lower Realized Risk ILAG
Unified Institutional Score
Composite Signal
49.6 / 100 (HOLD) 37.6 / 100 (SELL) Higher Composite ILAG
Trailing 12M Revenue (USD)
Operating Scale
$4.5M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
1.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M EBITDA ($1.66 Book/Sh · -215.3% ROE) -$20M ($0.24 Book/Sh · -341.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MAIA +34.41 pp
ILAG: -37.04% · MAIA: -2.63%
3M Horizon MAIA +30.41 pp
ILAG: -51.12% · MAIA: -20.71%
6M Horizon MAIA +44.86 pp
ILAG: -60.77% · MAIA: -15.91%
1Y Horizon ILAG +192.87 pp
ILAG: +213.52% · MAIA: +20.65%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ILAG vs MAIA. Trailing 12-month operating profitability (ILAG -279.6% vs MAIA 0.0%) and valuation multiples (ILAG N/M vs MAIA 1.2x Forward P/E) are benchmarked directly in Pillar 4 below.

ILAG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.5M
Gross Margin1.2%
Op. Margin-279.6%
ROE / Fwd P/E-215.3% · N/M
MAIA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-341.5% · 1.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ILAG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ILAG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MAIA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MAIA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ILAG Moat Profile Cyclical / Execution-Driven Positioning
Building Products & Equipment Operator
Competes within the Building Products & Equipment value chain with $3.3M market capitalization and -279.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MAIA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $68.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ILAG vs MAIA Key Questions & Quantitative Answers

As of Nov 20, 2026, Intelligent Living Application Group Inc. (ILAG) is the stronger overall head-to-head candidate over MAIA Biotechnology, Inc. (MAIA) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ILAG carries a Unified Composite Score of 49.6/100 (HOLD) at $1.53 (N/M Forward P/E, -279.6% operating margin), whereas MAIA carries 37.6/100 (SELL) at $1.11 (1.2x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ILAG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2); meanwhile MAIA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ILAG leads the Growth & Scale pillar: ILAG posts +2.3% YoY revenue growth and +0.0% YoY earnings growth on $4.5M TTM revenue (1.2% gross margin, -279.6% operating margin), compared with MAIA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ILAG generates $4.5M in USD-normalized revenue versus N/A for MAIA. In operating R&D and SG&A reinvestment, ILAG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MAIA.

MAIA screens cheaper on headline valuation multiples. ILAG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (unreported EBITDA margin), whereas MAIA trades at 1.2x Forward P/E, 1.2x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ILAG (-215.3% ROE) versus MAIA (-341.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ILAG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 94% Vol realized risk). By comparison, MAIA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.65β · 108% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.